Serum M30 levels are associated with survival in advanced gastric carcinoma patients

Yaman, Emel; Coşkun, Uğur; Sancak, Banu; Büyükberber, Süleyman; Öztürk, Bayram; Benekli, Mustafa

doi:10.1016/j.intimp.2010.03.013

Cited by 32 publications

(30 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum M65 and M30 levels were shown to be elevated in patients with different types of carcinoma (64)(65)(66)(67)(68). The measurement of caspase-cleaved or total CK18 from epithelial-derived tumors could be a simple, noninvasive way to monitor or predict tumor progression (69), prognosis (64,65,69,70), and response to chemotherapy (66)(67)(68)(70)(71)(72).…”

Section: Clinical Applications Of Ck18mentioning

confidence: 99%

See 1 more Smart Citation

Biological Functions of Cytokeratin 18 in Cancer

Weng

Cui²,

Fang³

2012

Molecular Cancer Research

View full text Add to dashboard Cite

The structural proteins cytokeratin 18 (CK18) and its coexpressed complementary partner CK8 are expressed in a variety of adult epithelial organs and may play a role in carcinogenesis. In this study, we focused on the biological functions of CK18, which is thought to modulate intracellular signaling and operates in conjunction with various related proteins. CK18 may affect carcinogenesis through several signaling pathways, including the phosphoinositide 3-kinase (PI3K)/Akt, Wnt, and extracellular signal-regulated kinase (ERK) mitogen-activated protein kinase (MAPK) signaling pathways. CK18 acts as an identical target of Akt in the PI3K/Akt pathway and of ERK1/2 in the ERK MAPK pathway, and regulation of CK18 by Wnt is involved in Akt activation. Finally, we discuss the importance of gaining a more complete understanding of the expression of CK18 during carcinogenesis, and suggest potential clinical applications of that understanding. Mol Cancer Res; 10(4); 485-93. Ó2012 AACR.

show abstract

Section: Clinical Applications Of Ck18mentioning

confidence: 99%

“…The measurement of caspase-cleaved or total CK18 from epithelial-derived tumors could be a simple, noninvasive way to monitor or predict tumor progression (69), prognosis (64,65,69,70), and response to chemotherapy (66)(67)(68)(70)(71)(72).…”

Section: Clinical Applications Of Ck18mentioning

confidence: 99%

Biological Functions of Cytokeratin 18 in Cancer

Weng

Cui²,

Fang³

2012

Molecular Cancer Research

View full text Add to dashboard Cite

show abstract

“…Serum levels of M30 and M65 significantly reflected the prognosis of testicular germ cell cancer [21]. Yaman E et al reported that serum M30 level was an independent prognostic factor in patients with gastric cancer, but serum M65 level was not a prognostic factor [26]. In Bilici's study, univariate analysis showed that M30 and M65 levels were associated with progression-free survival in patients with advanced gastric cancer, but these findings could not be confirmed by multivariate analysis [29].…”

Section: Discussionmentioning

confidence: 99%

“…Yaman E et al reported that serum M30 and M65 levels were increased in patients with advanced gastric cancer, and only M30 levels reflected the tumor load [26]. There were no reports that indicate correlation between serum M30 and M65 levels and cancer extent.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Serum cytokeratin 18 as a biomarker for gastric cancer

et al. 2012

View full text Add to dashboard Cite

Cytokeratin 18 (CK18) fragments are released into circulation during epithelial cell death. M30 (reflect caspase cleaved CK18 fragment) and M65 (reflect total CK18 fragment) enzyme-linked immunosorbent assay (ELISA) detects circulating CK18 fragments released during caspase-dependent or total cell death, respectively; thus, CK18 has the potential of being a biomarker for epithelial cancers. In the present study, we investigated the serum levels of M30 and M65 in patients with gastric cancer, determined correlation of these levels with clinical features, and evaluated the usefulness of these enzymes as diagnostic and prognostic markers.We enrolled 54 gastric cancer patients and 12 healthy volunteers in this study. We measured the serum levels of M30 and M65 by quantitative ELISA.The levels of M30 and M65 in gastric cancer patients were significantly higher than those in healthy volunteers (P = 0.001, P < 0.001). The enzyme levels were elevated with the progress of gastric cancer. The sensitivity and specificity of M30 as a diagnostic marker were 67.5% and 90.9%, respectively, and those of M65 were 70.1% and 90.9%, respectively. The serum levels of M30 and M65 in patient with early gastric cancer were elevated in 38.1% and 66.7%, respectively. Further, increased serum level of M65 is an independent indicator of poor prognosis (P = 0.036).The serum levels of M30 and M65 may be useful biomarkers for gastric cancer as diagnostic markers that can reflect the extent of cancer. Moreover, M65 levels can be 3 used as a prognostic indicator.

show abstract